|
DK2752488T3
(da)
|
2002-11-18 |
2020-04-20 |
Roche Innovation Ct Copenhagen As |
Antisense-design
|
|
CN104212799B
(zh)
|
2008-10-15 |
2018-11-23 |
Ionis制药公司 |
因子11表达的调节
|
|
RU2015151857A
(ru)
|
2008-12-02 |
2019-01-15 |
Уэйв Лайф Сайенсес Джапан, Инк. |
Способ синтеза модифицированных по атому фосфора нуклеиновых кислот
|
|
MX342945B
(es)
|
2009-07-06 |
2016-10-18 |
Ontorii Inc * |
Profármacos de ácido nucleico novedosos y métodos de uso de los mismos.
|
|
US10428019B2
(en)
|
2010-09-24 |
2019-10-01 |
Wave Life Sciences Ltd. |
Chiral auxiliaries
|
|
AU2011329777B2
(en)
|
2010-11-17 |
2016-06-09 |
Ionis Pharmaceuticals, Inc. |
Modulation of alpha synuclein expression
|
|
EP3248982A1
(en)
|
2011-07-19 |
2017-11-29 |
Wave Life Sciences Ltd. |
Thiosulfonate reagents for the synthesis of functionalized nucleic acids
|
|
EP3533873A1
(en)
|
2011-09-14 |
2019-09-04 |
Translate Bio MA, Inc. |
Multimeric oligonucleotide compounds
|
|
US10837014B2
(en)
|
2012-05-16 |
2020-11-17 |
Translate Bio Ma, Inc. |
Compositions and methods for modulating SMN gene family expression
|
|
WO2013173638A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating smn gene family expression
|
|
EP2850188A4
(en)
|
2012-05-16 |
2016-01-20 |
Rana Therapeutics Inc |
COMPOSITIONS AND METHOD FOR MODULATING THE EXPRESSION OF THE HEMOGLOBIN GENE FAMILIES
|
|
CN104583401A
(zh)
|
2012-05-16 |
2015-04-29 |
Rana医疗有限公司 |
用于调节atp2a2表达的组合物和方法
|
|
JP2015518712A
(ja)
|
2012-05-16 |
2015-07-06 |
ラナ セラピューティクス インコーポレイテッド |
Ｍｅｃｐ２発現を調節するための組成物及び方法
|
|
JP2015518713A
(ja)
|
2012-05-16 |
2015-07-06 |
ラナ セラピューティクス インコーポレイテッド |
Ｕｔｒｎ発現を調節するための組成物及び方法
|
|
CA2879023C
(en)
|
2012-07-13 |
2017-03-28 |
Wave Life Sciences Japan |
Asymmetric auxiliary group
|
|
CN104661664B
(zh)
|
2012-07-13 |
2020-07-03 |
波涛生命科学有限公司 |
手性控制
|
|
WO2014043544A1
(en)
|
2012-09-14 |
2014-03-20 |
Rana Therapeutics, Inc. |
Multimeric oligonucleotide compounds
|
|
SG11201503821YA
(en)
|
2012-11-15 |
2015-06-29 |
Roche Innovation Ct Copenhagen As |
Oligonucleotide conjugates
|
|
RU2649367C2
(ru)
*
|
2013-01-30 |
2018-04-02 |
Ф. Хоффманн-Ля Рош Аг |
Конъюгаты углевода и lna-олигонуклеотида
|
|
TW201446791A
(zh)
|
2013-05-01 |
2014-12-16 |
Regulus Therapeutics Inc |
用於調節mir-122之微小rna化合物及方法
|
|
CA2909868C
(en)
|
2013-05-01 |
2021-10-19 |
Regulus Therapeutics Inc. |
Compounds and methods for enhanced cellular uptake
|
|
KR102482890B1
(ko)
|
2013-05-01 |
2022-12-30 |
아이오니스 파마수티컬즈, 인코포레이티드 |
아포지질단백질 (a) 발현을 조절하는 조성물 및 방법
|
|
US9943604B2
(en)
|
2013-09-20 |
2018-04-17 |
Ionis Pharmaceuticals, Inc. |
Targeted therapeutic nucleosides and their use
|
|
US11162096B2
(en)
|
2013-10-14 |
2021-11-02 |
Ionis Pharmaceuticals, Inc |
Methods for modulating expression of C9ORF72 antisense transcript
|
|
WO2015061536A1
(en)
|
2013-10-25 |
2015-04-30 |
Regulus Therapeutics Inc. |
Microrna compounds and methods for modulating mir-21 activity
|
|
US10144933B2
(en)
|
2014-01-15 |
2018-12-04 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
|
|
JPWO2015108048A1
(ja)
|
2014-01-15 |
2017-03-23 |
株式会社新日本科学 |
抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
|
|
MX2016009290A
(es)
|
2014-01-16 |
2017-02-28 |
Wave Life Sciences Ltd |
Diseño quiral.
|
|
CA2935426C
(en)
*
|
2014-01-30 |
2023-07-25 |
F. Hoffmann-La Roche Ag |
Polyoligomer compound with biocleavable conjugates for reducing or inhibiting expression of a nucleic acid target
|
|
US10006027B2
(en)
|
2014-03-19 |
2018-06-26 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating Ataxin 2 expression
|
|
WO2015143246A1
(en)
|
2014-03-19 |
2015-09-24 |
Isis Pharmaceuticals, Inc. |
Compositions for modulating ataxin 2 expression
|
|
MY192634A
(en)
|
2014-04-01 |
2022-08-29 |
Biogen Ma Inc |
Compositions for modulating sod-1 expression
|
|
CN106232125B
(zh)
|
2014-05-01 |
2020-10-16 |
Ionis制药公司 |
用于调节pkk表达的组合物和方法
|
|
CN110903337A
(zh)
|
2014-05-01 |
2020-03-24 |
Ionis制药公司 |
用于调节生长激素受体表达的组合物和方法
|
|
SI3137605T1
(sl)
|
2014-05-01 |
2021-02-26 |
Ionis Pharmaceuticals, Inc. |
Sestavki in metode za modulacijo ekspresije angiopoetin 3-podobnega
|
|
PE20170010A1
(es)
|
2014-05-01 |
2017-03-04 |
Ionis Pharmaceuticals Inc |
Composiciones y metodos para modular la expresion del factor b del complemento
|
|
GB201408623D0
(en)
|
2014-05-15 |
2014-07-02 |
Santaris Pharma As |
Oligomers and oligomer conjugates
|
|
RU2017105342A
(ru)
*
|
2014-08-07 |
2018-09-13 |
Регулус Терапьютикс Инк. |
НАЦЕЛИВАНИЕ НА микроРНК ПРИ РАССТРОЙСТВАХ ОБМЕНА ВЕЩЕСТВ
|
|
US10436802B2
(en)
|
2014-09-12 |
2019-10-08 |
Biogen Ma Inc. |
Methods for treating spinal muscular atrophy
|
|
KR20170068469A
(ko)
|
2014-10-10 |
2017-06-19 |
에프. 호프만-라 로슈 아게 |
ＧａｌＮＡｃ 포스포라미다이트, 그의 핵산 컨쥬게이트 및 그의 용도
|
|
JP2017534643A
(ja)
*
|
2014-11-10 |
2017-11-24 |
グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ |
Ｃ型肝炎のための組合せ長時間作用型組成物および方法
|
|
CN107208092B
(zh)
|
2014-12-16 |
2021-09-10 |
罗氏创新中心哥本哈根有限公司 |
手性毒性筛选方法
|
|
WO2016100716A1
(en)
|
2014-12-18 |
2016-06-23 |
Vasant Jadhav |
Reversirtm compounds
|
|
WO2016112132A1
(en)
|
2015-01-06 |
2016-07-14 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
|
WO2016115490A1
(en)
|
2015-01-16 |
2016-07-21 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of dux4
|
|
WO2016130943A1
(en)
*
|
2015-02-13 |
2016-08-18 |
Rana Therapeutics, Inc. |
Hybrid oligonucleotides and uses thereof
|
|
US11129844B2
(en)
|
2015-03-03 |
2021-09-28 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating MECP2 expression
|
|
WO2016161388A1
(en)
|
2015-04-03 |
2016-10-06 |
University Of Massachusetts |
Fully stabilized asymmetric sirna
|
|
CN116004624A
(zh)
|
2015-04-03 |
2023-04-25 |
马萨诸塞大学 |
用于靶向亨廷汀mRNA的寡核苷酸化合物
|
|
PT3277815T
(pt)
|
2015-04-03 |
2021-11-11 |
Beth Israel Deaconess Medical Ct Inc |
Compostos de oligonucleótidos para o tratamento de pré-eclâmpsia e outros distúrbios angiogénicos
|
|
US10407678B2
(en)
|
2015-04-16 |
2019-09-10 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of C9ORF72 antisense transcript
|
|
WO2017030973A1
(en)
*
|
2015-08-14 |
2017-02-23 |
University Of Massachusetts |
Bioactive conjugates for oligonucleotide delivery
|
|
DK3341479T3
(da)
|
2015-08-24 |
2020-02-24 |
Roche Innovation Ct Copenhagen As |
LNA-G-Proces
|
|
US20210052631A1
(en)
*
|
2015-09-25 |
2021-02-25 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
|
EP3355932B1
(en)
|
2015-10-02 |
2023-04-12 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide conjugation process
|
|
SG10201912902TA
(en)
|
2015-10-09 |
2020-02-27 |
Wave Life Sciences Ltd |
Oligonucleotide compositions and methods thereof
|
|
WO2017068087A1
(en)
|
2015-10-22 |
2017-04-27 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide detection method
|
|
DK4119569T3
(da)
*
|
2015-11-06 |
2024-08-12 |
Ionis Pharmaceuticals Inc |
Konjugerede antisense-forbindelser til anvendelse i behandling
|
|
CA2999341A1
(en)
|
2015-11-06 |
2017-05-11 |
Ionis Pharmaceuticals, Inc. |
Modulating apolipoprotein (a) expression
|
|
UA125963C2
(uk)
|
2015-11-12 |
2022-07-20 |
Ф. Хоффманн-Ля Рош Аг |
Олігонуклеотид для індукції батьківської експресії ube3a
|
|
WO2017096395A1
(en)
|
2015-12-04 |
2017-06-08 |
Ionis Pharmaceuticals, Inc. |
Methods of treating breast cancer
|
|
EP3397288A4
(en)
|
2015-12-31 |
2019-09-11 |
Ionis Pharmaceuticals, Inc. |
PROCESS FOR REDUCING ATAXIN-2 EXPRESSION
|
|
EP3400300A4
(en)
|
2016-01-05 |
2019-08-07 |
Ionis Pharmaceuticals, Inc. |
PROCESS FOR REDUCING LRRK2 EXPRESSION
|
|
ES2858090T3
(es)
*
|
2016-01-29 |
2021-09-29 |
Kyowa Kirin Co Ltd |
Complejo de ácidos nucleicos
|
|
JP7749201B6
(ja)
|
2016-01-31 |
2025-10-21 |
ユニバーシティー オブ マサチューセッツ |
分岐オリゴヌクレオチド
|
|
CN109069529B
(zh)
|
2016-03-07 |
2021-08-20 |
箭头药业股份有限公司 |
用于治疗性化合物的靶向配体
|
|
AR108038A1
(es)
|
2016-03-14 |
2018-07-11 |
Roche Innovation Ct Copenhagen As |
Oligonucleótidos para reducir la expresión de pd-l1 (ligando de muerte programada-1)
|
|
US10577607B2
(en)
|
2016-03-16 |
2020-03-03 |
Ionis Pharmaceuticals, Inc. |
Modulation of DYRK1B expression
|
|
EP3429690A4
(en)
|
2016-03-16 |
2019-10-23 |
Ionis Pharmaceuticals, Inc. |
METHOD FOR MODULATING KEAP1
|
|
MA45328A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Compositions acide nucléique-polypeptide et utilisations de celles-ci
|
|
EP3228326A1
(en)
*
|
2016-04-05 |
2017-10-11 |
Silence Therapeutics GmbH |
Nucleic acid linked to a trivalent glycoconjugate
|
|
JP7150608B6
(ja)
*
|
2016-04-08 |
2022-11-11 |
トランスレイト バイオ， インコーポレイテッド |
多量体コード核酸及びその使用
|
|
EP3442983A1
(en)
|
2016-04-14 |
2019-02-20 |
H. Hoffnabb-La Roche Ag |
TRITYL-MONO-Ga1NAc COMPOUNDS AND THEIR USE
|
|
KR102608220B1
(ko)
*
|
2016-05-06 |
2023-11-29 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Glp-1 수용체 리간드 모이어티 컨쥬게이트된 올리고뉴클레오티드 및 이의 용도
|
|
WO2017219017A1
(en)
|
2016-06-17 |
2017-12-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of gys1 expression
|
|
MA45496A
(fr)
|
2016-06-17 |
2019-04-24 |
Hoffmann La Roche |
Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
|
|
WO2017220751A1
(en)
|
2016-06-22 |
2017-12-28 |
Proqr Therapeutics Ii B.V. |
Single-stranded rna-editing oligonucleotides
|
|
RU2019101298A
(ru)
|
2016-07-01 |
2020-08-03 |
Ф. Хоффманн-Ля Рош Аг |
Антисмысловые олигонуклеотиды для модулирования экспрессии htra1
|
|
CA3033368A1
(en)
|
2016-08-12 |
2018-02-15 |
University Of Massachusetts |
Conjugated oligonucleotides
|
|
ES2837076T3
(es)
|
2016-09-01 |
2021-06-29 |
Proqr Therapeutics Ii Bv |
Oligonucleótidos para la edición de ARN de cadena sencilla modificados químicamente
|
|
CN109462981B
(zh)
|
2016-09-02 |
2023-07-07 |
箭头药业股份有限公司 |
靶向配体
|
|
CN109661233A
(zh)
|
2016-10-06 |
2019-04-19 |
Ionis 制药公司 |
缀合低聚化合物的方法
|
|
JOP20190104A1
(ar)
|
2016-11-10 |
2019-05-07 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن atxn3
|
|
WO2018102745A1
(en)
|
2016-12-02 |
2018-06-07 |
Cold Spring Harbor Laboratory |
Modulation of lnc05 expression
|
|
US20190367920A1
(en)
|
2017-01-13 |
2019-12-05 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating nfkb1 expression
|
|
EP3568480A1
(en)
|
2017-01-13 |
2019-11-20 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating nfkb2 expression
|
|
EP3568481A1
(en)
|
2017-01-13 |
2019-11-20 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating relb expression
|
|
US20190338286A1
(en)
|
2017-01-13 |
2019-11-07 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating rel expression
|
|
WO2018130581A1
(en)
|
2017-01-13 |
2018-07-19 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating rela expression
|
|
CN110536964A
(zh)
|
2017-03-10 |
2019-12-03 |
国立研究开发法人国立成育医疗研究中心 |
反义寡核苷酸和糖原贮积病Ia型预防或治疗用组合物
|
|
WO2018165541A1
(en)
*
|
2017-03-10 |
2018-09-13 |
The Board Of Regents Of The University Of Texas System |
Treatment of fuchs' endothelial corneal dystrophy
|
|
KR20250145702A
(ko)
|
2017-04-11 |
2025-10-13 |
아뷰터스 바이오파마 코포레이션 |
표적화 조성물
|
|
WO2018215049A1
(en)
*
|
2017-05-23 |
2018-11-29 |
F. Hoffmann-La Roche Ag |
Process for galnac oligonucleotide conjugates
|
|
EP3633036A4
(en)
|
2017-05-26 |
2021-03-17 |
National Cerebral and Cardiovascular Center |
NUCLEIC ACID TARGETING ANTI-SENSES PCSK9
|
|
US20190055564A1
(en)
|
2017-06-01 |
2019-02-21 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides for modulating htra1 expression
|
|
WO2018223073A1
(en)
*
|
2017-06-02 |
2018-12-06 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
WO2018226788A1
(en)
|
2017-06-07 |
2018-12-13 |
University Of Massachusetts |
Anti-adam33 oligonucleotides and related methods
|
|
CN110799647A
(zh)
|
2017-06-23 |
2020-02-14 |
马萨诸塞大学 |
双尾自递送sirna及相关的方法
|
|
WO2019030574A1
(en)
|
2017-08-10 |
2019-02-14 |
Cerenis Therapeutics Holding |
Cargomers
|
|
WO2019030313A2
(en)
|
2017-08-11 |
2019-02-14 |
Roche Innovation Center Copenhagen A/S |
OLIGONUCLEOTIDES FOR MODULATION OF UBE3C EXPRESSION
|
|
WO2019036612A1
(en)
|
2017-08-17 |
2019-02-21 |
Alnylam Pharmaceuticals, Inc. |
ADJUSTABLE REVERSIR TM COMPOUNDS
|
|
US11197884B2
(en)
|
2017-08-18 |
2021-12-14 |
Ionis Pharmaceuticals, Inc. |
Modulation of the notch signaling pathway for treatment of respiratory disorders
|
|
WO2019038228A1
(en)
|
2017-08-22 |
2019-02-28 |
Roche Innovation Center Copenhagen A/S |
OLIGONUCLEOTIDES FOR MODULATION OF TOM1 EXPRESSION
|
|
US10517889B2
(en)
|
2017-09-08 |
2019-12-31 |
Ionis Pharmaceuticals, Inc. |
Modulators of SMAD7 expression
|
|
WO2019075357A1
(en)
*
|
2017-10-12 |
2019-04-18 |
Wave Life Sciences Ltd. |
OLIGONUCLEOTIDE COMPOSITIONS AND RELATED METHODS
|
|
JP2021502059A
(ja)
|
2017-10-13 |
2021-01-28 |
ロシュ イノベーション センター コペンハーゲン エーエス |
部分的に立体定義されたオリゴヌクレオチドのサブライブラリーを使用することによる、アンチセンスオリゴヌクレオチドの、改良された立体定義されたホスホロチオエートオリゴヌクレオチド変異体を同定するための方法
|
|
AU2018350693B2
(en)
|
2017-10-16 |
2021-03-04 |
F. Hoffmann-La Roche Ag |
Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection
|
|
EP3706729A4
(en)
|
2017-11-06 |
2021-12-01 |
Nitto Denko Corporation |
FUSOGENIC COMPOUNDS FOR THE ADMINISTRATION OF BIOLOGICALLY ACTIVE MOLECULES
|
|
TWI809004B
(zh)
|
2017-11-09 |
2023-07-21 |
美商Ionis製藥公司 |
用於降低snca表現之化合物及方法
|
|
US11414661B2
(en)
|
2017-12-01 |
2022-08-16 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
|
|
WO2019105418A1
(zh)
|
2017-12-01 |
2019-06-06 |
苏州瑞博生物技术有限公司 |
双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途
|
|
US11414665B2
(en)
|
2017-12-01 |
2022-08-16 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
|
|
JP7365052B2
(ja)
|
2017-12-01 |
2023-10-19 |
スーチョウ リボ ライフ サイエンス カンパニー、リミテッド |
核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
|
|
KR102834361B1
(ko)
|
2017-12-01 |
2025-07-17 |
쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 |
핵산, 이를 포함하는 조성물과 컨쥬게이트, 및 그의 제조 방법과 용도
|
|
CN118667812A
(zh)
|
2017-12-06 |
2024-09-20 |
艾维迪提生物科学公司 |
治疗肌萎缩和强直性肌营养不良的组合物和方法
|
|
CN111344408A
(zh)
|
2017-12-11 |
2020-06-26 |
哥本哈根罗氏创新中心 |
用于调控fndc3b表达的寡核苷酸
|
|
WO2019115417A2
(en)
|
2017-12-12 |
2019-06-20 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating rb1 expression
|
|
WO2019126641A2
(en)
|
2017-12-21 |
2019-06-27 |
Ionis Pharmaceuticals, Inc. |
Modulation of frataxin expression
|
|
CN111512160B
(zh)
|
2017-12-21 |
2024-04-09 |
豪夫迈·罗氏有限公司 |
Htra1 rna拮抗剂的伴随诊断
|
|
CN111757936B
(zh)
|
2017-12-22 |
2025-07-04 |
罗氏创新中心哥本哈根有限公司 |
包含二硫代磷酸酯核苷间连接的寡核苷酸
|
|
US20200332289A1
(en)
|
2017-12-22 |
2020-10-22 |
Roche Innovation Center Copenhagen A/S |
Gapmer oligonucleotides comprising a phosphorodithioate internucleoside linkage
|
|
US11597926B2
(en)
|
2017-12-22 |
2023-03-07 |
Roche Innovation Center Copenhagen A/S |
Thiophosphoramidites
|
|
CA3087106A1
(en)
*
|
2017-12-29 |
2019-07-04 |
Suzhou Ribo Life Science Co., Ltd. |
Conjugates and preparation and use thereof
|
|
WO2019137883A1
(en)
|
2018-01-10 |
2019-07-18 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating pias4 expression
|
|
KR102839166B1
(ko)
|
2018-01-12 |
2025-07-28 |
브리스톨-마이어스 스큅 컴퍼니 |
알파-시누클레인을 표적화하는 안티센스 올리고뉴클레오티드 및 그의 용도
|
|
JP2021510295A
(ja)
|
2018-01-12 |
2021-04-22 |
ロシュ イノベーション センター コペンハーゲン エーエス |
Ｇｓｋ３ｂ発現を調節するためのオリゴヌクレオチド
|
|
CA3088112A1
(en)
|
2018-01-12 |
2019-07-18 |
Bristol-Myers Squibb Company |
Antisense oligonucleotides targeting alpha-synuclein and uses thereof
|
|
JP2021511027A
(ja)
*
|
2018-01-12 |
2021-05-06 |
ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅ Ｉｎｎｏｖａｔｉｏｎ Ｃｅｎｔｅｒ Ｃｏｐｅｎｈａｇｅｎ Ａ／Ｓ |
アルファ−シヌクレインアンチセンスオリゴヌクレオチド及びその使用
|
|
AU2019206731A1
(en)
|
2018-01-15 |
2020-07-30 |
Ionis Pharmaceuticals, Inc. |
Modulators of DNM2 expression
|
|
EP3740574A1
(en)
|
2018-01-17 |
2020-11-25 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating erc1 expression
|
|
WO2019141723A1
(en)
|
2018-01-18 |
2019-07-25 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting srebp1
|
|
WO2019145386A1
(en)
|
2018-01-26 |
2019-08-01 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating csnk1d expression
|
|
EP3743116B1
(en)
*
|
2018-01-26 |
2024-07-10 |
F. Hoffmann-La Roche AG |
Radiolabelled oligonucleotides and process for their preparation
|
|
MA51795A
(fr)
*
|
2018-02-09 |
2020-12-16 |
Hoffmann La Roche |
Oligonucléotides pour moduler l'expression de tmem106b
|
|
IL320427A
(en)
|
2018-02-21 |
2025-06-01 |
Bristol Myers Squibb Co |
CAMK2D antisense oligonucleotides and their uses
|
|
EP3759127A4
(en)
|
2018-03-02 |
2022-03-30 |
Ionis Pharmaceuticals, Inc. |
COMPOUNDS AND METHODS FOR MODULATING AMYLOID BETA PRECURSOR PROTEIN
|
|
TWI840345B
(zh)
|
2018-03-02 |
2024-05-01 |
美商Ionis製藥公司 |
Irf4表現之調節劑
|
|
CN115976028B
(zh)
|
2018-03-09 |
2025-03-25 |
第一三共株式会社 |
糖原病Ia型治疗药
|
|
WO2019183440A1
(en)
|
2018-03-22 |
2019-09-26 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating fmr1 expression
|
|
EP3775208A1
(en)
|
2018-04-05 |
2021-02-17 |
F. Hoffmann-La Roche AG |
Use of fubp1 inhibitors for treating hepatitis b virus infection
|
|
US11365416B2
(en)
|
2018-04-11 |
2022-06-21 |
Ionis Pharmaceuticals, Inc. |
Modulators of EZH2 expression
|
|
EP3790990A1
(en)
|
2018-05-07 |
2021-03-17 |
Roche Innovation Center Copenhagen A/S |
Quality control of lna oligonucleotide therapeutics using massively parallel sequencing
|
|
CN112400020B
(zh)
|
2018-05-08 |
2024-11-19 |
莱古路斯治疗法股份有限公司 |
作为具有hcv抗病毒活性与降低的高胆红素血症副作用的mir-122抑制剂的galnac缀合的经修饰的寡核苷酸
|
|
WO2019215175A1
(en)
|
2018-05-08 |
2019-11-14 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating myh7 expression
|
|
US20210355497A1
(en)
|
2018-05-09 |
2021-11-18 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing fxi expression
|
|
WO2019217708A1
(en)
|
2018-05-09 |
2019-11-14 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing atxn3 expression
|
|
SG11202010841QA
(en)
*
|
2018-05-11 |
2020-11-27 |
Alpha Anomeric Sas |
Oligonucleotides conjugates comprising 7'-5'-alpha-anomeric-bicyclic sugar nucleosides
|
|
CA3098624A1
(en)
|
2018-05-11 |
2019-11-14 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
GB201808146D0
(en)
|
2018-05-18 |
2018-07-11 |
Proqr Therapeutics Ii Bv |
Stereospecific Linkages in RNA Editing Oligonucleotides
|
|
WO2019233922A1
(en)
|
2018-06-05 |
2019-12-12 |
F. Hoffmann-La Roche Ag |
Oligonucleotides for modulating atxn2 expression
|
|
WO2019241648A1
(en)
|
2018-06-14 |
2019-12-19 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for increasing stmn2 expression
|
|
TWI833770B
(zh)
|
2018-06-27 |
2024-03-01 |
美商Ionis製藥公司 |
用於減少 lrrk2 表現之化合物及方法
|
|
WO2020007702A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting bcl2l11
|
|
WO2020007700A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting spi1
|
|
WO2020007772A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting gbp-1
|
|
MY206038A
(en)
|
2018-07-03 |
2024-11-26 |
Hoffmann La Roche |
Oligonucleotides for modulating tau expression
|
|
WO2020007826A1
(en)
|
2018-07-05 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting mbtps1
|
|
WO2020007889A1
(en)
|
2018-07-05 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting stat1
|
|
WO2020011743A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting mafb
|
|
WO2020011653A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting kynu
|
|
WO2020011745A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting cers6
|
|
WO2020011869A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting tlr2
|
|
WO2020011744A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting cers5
|
|
MX2021000404A
(es)
|
2018-07-13 |
2021-03-25 |
Hoffmann La Roche |
Oligonucleotidos para modular la expresion de rtel1.
|
|
MX2021000922A
(es)
|
2018-07-25 |
2021-03-31 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para reducir la expresion de la atxn2.
|
|
CN112513060B
(zh)
|
2018-07-31 |
2024-08-06 |
罗氏创新中心哥本哈根有限公司 |
包含三硫代磷酸酯核苷间键的寡核苷酸
|
|
US20210221837A1
(en)
*
|
2018-07-31 |
2021-07-22 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides comprising a phosphorotrithioate internucleoside linkage
|
|
EP3833763A4
(en)
|
2018-08-10 |
2023-07-19 |
University of Massachusetts |
MODIFIED OLIGONUCLEOTIDES FOR TARGETING SNPS
|
|
JP2021533800A
(ja)
|
2018-08-21 |
2021-12-09 |
スーチョウ リボ ライフ サイエンス カンパニー、リミテッドSuzhou Ribo Life Science Co., Ltd. |
核酸、当該核酸を含む薬物組成物及び複合体ならびにその使用
|
|
WO2020038971A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting vcan
|
|
US11279930B2
(en)
|
2018-08-23 |
2022-03-22 |
University Of Massachusetts |
O-methyl rich fully stabilized oligonucleotides
|
|
EP3841220A1
(en)
|
2018-08-23 |
2021-06-30 |
Roche Innovation Center Copenhagen A/S |
Microrna-134 biomarker
|
|
WO2020038976A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting usp8
|
|
WO2020038973A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting sptlc1
|
|
EP3844274A1
(en)
|
2018-08-28 |
2021-07-07 |
Roche Innovation Center Copenhagen A/S |
Neoantigen engineering using splice modulating compounds
|
|
EP3620519A1
(en)
|
2018-09-04 |
2020-03-11 |
F. Hoffmann-La Roche AG |
Use of isolated milk extracellular vesicles for delivering oligonucleotides orally
|
|
US20220056443A1
(en)
*
|
2018-09-06 |
2022-02-24 |
Aptamir Therapeutics, Inc. |
Metabolic benefits of short mir-22 mirna antagomir therapies
|
|
CN111655297A
(zh)
|
2018-09-30 |
2020-09-11 |
苏州瑞博生物技术有限公司 |
一种siRNA缀合物及其制备方法和用途
|
|
EP3873920A1
(en)
|
2018-11-01 |
2021-09-08 |
F. Hoffmann-La Roche AG |
Antisense oligonucleotides targeting tia1
|
|
TW202028222A
(zh)
|
2018-11-14 |
2020-08-01 |
美商Ionis製藥公司 |
Foxp3表現之調節劑
|
|
WO2020102630A1
(en)
|
2018-11-15 |
2020-05-22 |
Ionis Pharmaceuticals, Inc. |
Modulators of irf5 expression
|
|
MY205095A
(en)
|
2018-11-21 |
2024-10-01 |
Ionis Pharmaceuticals Inc |
Compounds and methods for reducing prion expression
|
|
US12485136B2
(en)
|
2018-12-03 |
2025-12-02 |
Takeda Pharmaceuticals U.S.A., Inc. |
Methods for the treatment of trinucleotide repeat expansion disorders associated with MLH3 activity
|
|
CN113631709A
(zh)
|
2018-12-20 |
2021-11-09 |
普拉克西斯精密药物股份有限公司 |
用于治疗kcnt1相关病症的组合物和方法
|
|
WO2020136125A2
(en)
|
2018-12-21 |
2020-07-02 |
Boehringer Ingelheim International Gmbh |
Antisense oligonucleotides targeting card9
|
|
JP2022523467A
(ja)
|
2019-01-18 |
2022-04-25 |
ユニバーシティ・オブ・マサチューセッツ |
動的な薬物動態を修飾するアンカー
|
|
JP2022518500A
(ja)
*
|
2019-01-25 |
2022-03-15 |
エフ．ホフマン－ラ ロシュ アーゲー |
経口薬物送達のための脂質小胞
|
|
US11214803B2
(en)
|
2019-01-31 |
2022-01-04 |
Ionis Pharmaceuticals, Inc. |
Modulators of YAP1 expression
|
|
CN113490742A
(zh)
*
|
2019-02-20 |
2021-10-08 |
罗氏创新中心哥本哈根有限公司 |
膦酰基乙酸酯缺口聚物寡核苷酸
|
|
CA3129646A1
(en)
|
2019-02-20 |
2020-08-27 |
Roche Innovation Center Copenhagen A/S |
Novel phosphoramidites
|
|
CN113474633A
(zh)
|
2019-02-26 |
2021-10-01 |
罗氏创新中心哥本哈根有限公司 |
寡核苷酸配制方法
|
|
KR20210134686A
(ko)
|
2019-02-27 |
2021-11-10 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Malat1 발현의 조절인자
|
|
JP2022522898A
(ja)
*
|
2019-03-05 |
2022-04-20 |
エフ．ホフマン－ラ ロシュ アーゲー |
分子の細胞内標的化
|
|
CN117431244A
(zh)
|
2019-03-29 |
2024-01-23 |
Ionis制药公司 |
用于调节ube3a-ats的化合物和方法
|
|
CA3132178A1
(en)
|
2019-04-02 |
2020-10-08 |
Aliye Seda Yilmaz-Elis |
Antisense oligonucleotides for immunotherapy
|
|
BR112021019182A2
(pt)
|
2019-04-03 |
2022-05-31 |
Bristol Myers Squibb Co |
Oligonucleotídeos angptl2 antissenso e seus usos
|
|
US11286485B2
(en)
|
2019-04-04 |
2022-03-29 |
Hoffmann-La Roche Inc. |
Oligonucleotides for modulating ATXN2 expression
|
|
JP7499267B2
(ja)
|
2019-04-04 |
2024-06-13 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ａｔｘｎ２発現を調節するためのオリゴヌクレオチド
|
|
SG11202112741XA
(en)
|
2019-05-31 |
2021-12-30 |
Aligos Therapeutics Inc |
Modified gapmer oligonucleotides and methods of use
|
|
CN113950529A
(zh)
|
2019-06-06 |
2022-01-18 |
豪夫迈·罗氏有限公司 |
靶向atxn3的反义寡核苷酸
|
|
EP4660307A2
(en)
|
2019-07-26 |
2025-12-10 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating gfap
|
|
CA3144467A1
(en)
*
|
2019-07-30 |
2021-02-04 |
Jonathan Miles Brown |
Subcutaneous delivery of multimeric oligonucleotides with enhanced bioactivity
|
|
CN114502730A
(zh)
|
2019-08-09 |
2022-05-13 |
马萨诸塞大学 |
经化学修饰的靶向snp的寡核苷酸
|
|
CA3150715A1
(en)
|
2019-09-10 |
2021-03-18 |
Makoto Koizumi |
Conjugate of galnac-oligonucleotide for delivery to liver and manufacturing method thereof
|
|
US12365894B2
(en)
|
2019-09-16 |
2025-07-22 |
University Of Massachusetts |
Branched lipid conjugates of siRNA for specific tissue delivery
|
|
AU2020356931A1
(en)
*
|
2019-10-02 |
2022-05-26 |
Sirnaomics, Inc. |
Oligonucleotides with nucleoside analogs
|
|
JP2023506954A
(ja)
|
2019-12-19 |
2023-02-20 |
エフ． ホフマン－ラ ロシュ エージー． |
Ｂ型肝炎ウイルス感染を処置するためのｓａｒａｆ阻害剤の使用
|
|
CN114829599A
(zh)
|
2019-12-19 |
2022-07-29 |
豪夫迈·罗氏有限公司 |
Scamp3抑制剂用于治疗乙型肝炎病毒感染的用途
|
|
EP4077670A1
(en)
|
2019-12-19 |
2022-10-26 |
F. Hoffmann-La Roche AG |
Use of cops3 inhibitors for treating hepatitis b virus infection
|
|
WO2021127650A1
(en)
*
|
2019-12-19 |
2021-06-24 |
Entrada Therapeutics, Inc. |
Compositions for delivery of antisense compounds
|
|
CN114901821A
(zh)
*
|
2019-12-19 |
2022-08-12 |
豪夫迈·罗氏有限公司 |
Sept9抑制剂用于治疗乙型肝炎病毒感染的用途
|
|
JP2023506550A
(ja)
|
2019-12-19 |
2023-02-16 |
エフ． ホフマン－ラ ロシュ エージー． |
Ｂ型肝炎ウイルス感染症を処置するためのｓｂｄｓ阻害剤の使用
|
|
US20210214727A1
(en)
|
2019-12-20 |
2021-07-15 |
Hoffmann-La Roche Inc. |
Enhanced oligonucleotides for inhibiting scn9a expression
|
|
CA3163490A1
(en)
|
2019-12-24 |
2021-07-01 |
F. Hoffman-La Roche Ag |
Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv
|
|
WO2021130270A1
(en)
|
2019-12-24 |
2021-07-01 |
F. Hoffmann-La Roche Ag |
Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv
|
|
EP4097234A1
(en)
|
2020-01-28 |
2022-12-07 |
Université de Strasbourg |
Antisense oligonucleotide targeting linc00518 for treating melanoma
|
|
WO2021158810A1
(en)
|
2020-02-05 |
2021-08-12 |
Bristol-Myers Squibb Company |
Oligonucleotides for splice modulation of camk2d
|
|
JP2023516142A
(ja)
|
2020-02-28 |
2023-04-18 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｃｄ７３エクソン７スプライシングを調節するためのオリゴヌクレオチド
|
|
AR121446A1
(es)
|
2020-02-28 |
2022-06-08 |
Ionis Pharmaceuticals Inc |
Compuestos y métodos para modular smn2
|
|
MX2022010980A
(es)
|
2020-03-04 |
2022-12-02 |
Verve Therapeutics Inc |
Composiciones y metodos para el suministro de arn dirigido.
|
|
EP4121063A4
(en)
|
2020-03-19 |
2024-07-03 |
Avidity Biosciences, Inc. |
COMPOSITIONS AND METHODS FOR TREATING FACIO-SCAPULO-HUMERAL MUSCULAR DYSTROPHY
|
|
EP4138858A4
(en)
*
|
2020-04-21 |
2024-07-03 |
Flagship Pioneering, Inc. |
BIFUNCTIONAL MOLECULES AND METHODS OF USE THEREOF
|
|
JP7738573B2
(ja)
|
2020-05-01 |
2025-09-12 |
アイオーニス ファーマシューティカルズ， インコーポレーテッド |
Ａｔｘｎ１を調節するための化合物及び方法
|
|
EP4150085A1
(en)
|
2020-05-11 |
2023-03-22 |
Genentech, Inc. |
Complement component c1r inhibitors for treating a neurological disease, and related compositions, systems and methods of using same
|
|
EP4150084A1
(en)
|
2020-05-11 |
2023-03-22 |
Genentech, Inc. |
Complement component 4 inhibitors for treating neurological diseases, and related compositons, systems and methods of using same
|
|
EP4149486A1
(en)
|
2020-05-11 |
2023-03-22 |
Genentech, Inc. |
Complement component c1s inhibitors for treating a neurological disease, and related compositions, systems and methods of using same
|
|
TW202208628A
(zh)
|
2020-05-13 |
2022-03-01 |
瑞士商赫孚孟拉羅股份公司 |
靶向顆粒蛋白前體之寡核苷酸促效劑
|
|
EP4150086A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
|
|
CA3162416C
(en)
|
2020-05-15 |
2023-07-04 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
|
|
EP4150087A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
|
|
WO2021231698A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
|
|
WO2021231680A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
|
|
WO2021231692A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of otoferlin (otof)
|
|
EP4150089A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of retinoschisin 1 (rs1)
|
|
EP4150077A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
|
|
CN115884777A
(zh)
|
2020-05-22 |
2023-03-31 |
豪夫迈·罗氏有限公司 |
用于card9的剪接调节的寡核苷酸
|
|
AR122534A1
(es)
|
2020-06-03 |
2022-09-21 |
Triplet Therapeutics Inc |
Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3
|
|
US20230212572A1
(en)
|
2020-06-09 |
2023-07-06 |
Roche Innovation Center Copenhagen A/S |
Guanosine Analogues for Use in Therapeutics Polynucleotides
|
|
AR122731A1
(es)
|
2020-06-26 |
2022-10-05 |
Hoffmann La Roche |
Oligonucleótidos mejorados para modular la expresión de fubp1
|
|
CN116096899A
(zh)
|
2020-06-29 |
2023-05-09 |
Ionis制药公司 |
调节plp1的化合物和方法
|
|
JP2023534557A
(ja)
|
2020-07-23 |
2023-08-09 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ｒｎａ結合タンパク質部位を標的とするオリゴヌクレオチド
|
|
WO2022018155A1
(en)
|
2020-07-23 |
2022-01-27 |
F. Hoffmann-La Roche Ag |
Lna oligonucleotides for splice modulation of stmn2
|
|
UY39344A
(es)
|
2020-07-28 |
2022-02-25 |
Ionis Pharmaceuticals Inc |
Compuestos y métodos para reducir la expresión de app
|
|
CN111671913B
(zh)
*
|
2020-07-30 |
2022-02-08 |
四川大学 |
一种量子点-小核酸偶联物及其用途
|
|
CA3186935A1
(en)
|
2020-08-07 |
2022-02-10 |
Paymaan JAFAR-NEJAD |
Compounds and methods for modulating scn2a
|
|
EP4200419A2
(en)
|
2020-08-21 |
2023-06-28 |
F. Hoffmann-La Roche AG |
Use of a1cf inhibitors for treating hepatitis b virus infection
|
|
CA3194161A1
(en)
*
|
2020-10-02 |
2022-04-07 |
David M. Evans |
Nucleoside containing sirnas for treating viral diseases
|
|
TW202227101A
(zh)
|
2020-11-18 |
2022-07-16 |
美商Ionis製藥公司 |
用於調節血管收縮素原表現之化合物及方法
|
|
AR124227A1
(es)
|
2020-12-03 |
2023-03-01 |
Hoffmann La Roche |
Oligonucleótidos antisentido que actúan sobre atxn3
|
|
AR124229A1
(es)
|
2020-12-03 |
2023-03-01 |
Hoffmann La Roche |
Oligonucleótidos antisentido que actúan sobre atxn3
|
|
EP4263831A1
(en)
|
2020-12-18 |
2023-10-25 |
F. Hoffmann-La Roche AG |
Antisense oligonucleotides for targeting progranulin
|
|
TW202242111A
(zh)
|
2020-12-18 |
2022-11-01 |
美商Ionis製藥公司 |
用於調節因子ｘｉｉ之化合物及方法
|
|
JP2024501662A
(ja)
|
2020-12-22 |
2024-01-15 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ｘｂｐ１を標的とするオリゴヌクレオチド
|
|
CN114716518A
(zh)
*
|
2021-01-06 |
2022-07-08 |
圣诺制药公司 |
一种能够抑制pcsk9表达的分子构造及药物组合物
|
|
US20240083990A1
(en)
|
2021-01-26 |
2024-03-14 |
Universite Brest Bretagne Occidentale |
Novel stim1 splicing variants and uses thereof
|
|
TW202246500A
(zh)
|
2021-02-02 |
2022-12-01 |
瑞士商赫孚孟拉羅股份公司 |
用於抑制 ｒｔｅｌ１ 表現之增強型寡核苷酸
|
|
AU2022234522A1
(en)
|
2021-03-08 |
2023-10-26 |
Les Laboratoires Servier |
Antisense oligonucleotides for inhibiting alpha-synuclein expression
|
|
WO2022232650A1
(en)
*
|
2021-04-30 |
2022-11-03 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing agt expression
|
|
EP4341405A1
(en)
|
2021-05-20 |
2024-03-27 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
|
WO2022256283A2
(en)
|
2021-06-01 |
2022-12-08 |
Korro Bio, Inc. |
Methods for restoring protein function using adar
|
|
WO2022258555A1
(en)
|
2021-06-08 |
2022-12-15 |
F. Hoffmann-La Roche Ag |
Oligonucleotide progranulin agonists
|
|
US12378267B2
(en)
|
2021-06-17 |
2025-08-05 |
Entrada Therapeutics, Inc. |
Synthesis of FMOC-protected morpholino monomers and oligomers
|
|
MX2023015230A
(es)
|
2021-06-18 |
2024-01-18 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para reducir la expresion de ifnar1.
|
|
EP4359539A4
(en)
|
2021-06-23 |
2025-05-14 |
University Of Massachusetts |
ANTI-FLT1 OLIGONUCLEOTIDE COMPOUNDS OPTIMIZED FOR THE TREATMENT OF PREECLAMPSIA AND OTHER ANGIOGENIC DISORDERS
|
|
WO2023278410A1
(en)
|
2021-06-29 |
2023-01-05 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
|
US20230194709A9
(en)
|
2021-06-29 |
2023-06-22 |
Seagate Technology Llc |
Range information detection using coherent pulse sets with selected waveform characteristics
|
|
US20250188455A1
(en)
*
|
2021-09-02 |
2025-06-12 |
Vanderbilt University |
Lipophilic oligonucleotide conjugates
|
|
KR20240055874A
(ko)
|
2021-09-16 |
2024-04-29 |
어비디티 바이오사이언시스 인크. |
안면견갑상완 근이영양증을 치료하는 조성물 및 방법
|
|
CA3234835A1
(en)
|
2021-10-22 |
2023-04-27 |
Korro Bio, Inc. |
Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
|
|
JP2024540271A
(ja)
|
2021-11-03 |
2024-10-31 |
エフ． ホフマン－ラ ロシュ アーゲー |
アポリポタンパク質ｅ４発現を調節するためのオリゴヌクレオチド
|
|
KR20240101580A
(ko)
|
2021-11-11 |
2024-07-02 |
에프. 호프만-라 로슈 아게 |
Hbv 치료를 위한 약학 조합물
|
|
CA3241316A1
(en)
*
|
2021-12-03 |
2023-06-08 |
Quralis Corporation |
Gapmer antisense oligonucleotides with modified backbone chemistries
|
|
CN118434858A
(zh)
|
2021-12-07 |
2024-08-02 |
豪夫迈·罗氏有限公司 |
靶向actl6b的反义寡核苷酸
|
|
JP2024546887A
(ja)
|
2021-12-17 |
2024-12-26 |
ジェネンテック， インコーポレイテッド |
オリゴヌクレオチドｇｂａアゴニスト
|
|
JP2024546993A
(ja)
|
2021-12-17 |
2024-12-26 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ｒｔｅｌ１及びｆｕｂｐ１を調節するためのオリゴヌクレオチドの組み合わせ
|
|
JP2024547071A
(ja)
|
2021-12-20 |
2024-12-26 |
エフ． ホフマン－ラ ロシュ アーゲー |
トレオース核酸アンチセンスオリゴヌクレオチドおよびその方法
|
|
CN118613268A
(zh)
|
2022-01-20 |
2024-09-06 |
基因泰克公司 |
用于调节tmem106b表达的反义寡核苷酸
|
|
AR128558A1
(es)
|
2022-02-21 |
2024-05-22 |
Hoffmann La Roche |
Oligonucleótido antisentido
|
|
CN118871585A
(zh)
|
2022-03-16 |
2024-10-29 |
第一三共株式会社 |
具有RNAi活性的化学-修饰的寡核苷酸
|
|
CN118891366A
(zh)
|
2022-03-16 |
2024-11-01 |
第一三共株式会社 |
抑制转铁蛋白受体2的表达的siRNA
|
|
WO2023217890A1
(en)
|
2022-05-10 |
2023-11-16 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting cfp-elk1 intergene region
|
|
JP2025518522A
(ja)
|
2022-05-18 |
2025-06-17 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ｒｎａ結合タンパク質部位を標的とする改善されたオリゴヌクレオチド
|
|
EP4282964A1
(en)
*
|
2022-05-23 |
2023-11-29 |
Universitat de Valéncia |
Oligonucleotides conjugated to oleic acid and uses thereof
|
|
JP2025520514A
(ja)
|
2022-06-17 |
2025-07-03 |
エフ． ホフマン－ラ ロシュ アーゲー |
プログラニュリンを標的とするためのアンチセンスオリゴヌクレオチド
|
|
EP4332221A1
(en)
|
2022-08-29 |
2024-03-06 |
Roche Innovation Center Copenhagen A/S |
Threose nucleic acid antisense oligonucleotides and methods thereof
|
|
TW202421206A
(zh)
|
2022-09-06 |
2024-06-01 |
瑞士商赫孚孟拉羅股份公司 |
用於投予至眼睛之雙股ｒｎａ分子
|
|
KR20250075637A
(ko)
|
2022-09-23 |
2025-05-28 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Mecp2 발현을 감소시키기 위한 화합물 및 방법(compounds and methods for reducing mecp2 expression)
|
|
CN120529923A
(zh)
*
|
2022-11-21 |
2025-08-22 |
肽世代公司 |
细胞穿透肽、其缀合物及其使用方法
|
|
WO2024126654A1
(en)
|
2022-12-14 |
2024-06-20 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting actl6b
|
|
EP4652273A1
(en)
|
2023-01-16 |
2025-11-26 |
Institut National de la Recherche pour l'Agriculture, l'Alimentation et l'Environnement |
Antisense molecules and their uses for the treatment of coronavirus infection, in particular the treatment of covid-19 related to sars-cov-2 infection
|
|
WO2024155957A1
(en)
|
2023-01-19 |
2024-07-25 |
Altos Labs, Inc. |
Use of regeneration factors in organ transplantation
|
|
WO2024196893A1
(en)
*
|
2023-03-17 |
2024-09-26 |
Camford Labs Inc. |
Chemically modified nucleotides
|
|
CN121002179A
(zh)
*
|
2023-03-30 |
2025-11-21 |
中美瑞康核酸技术(南通)研究院有限公司 |
寡核苷酸的递送载体及其使用方法
|
|
WO2024227765A2
(en)
|
2023-05-04 |
2024-11-07 |
F. Hoffmann-La Roche Ag |
Oligonucleotides capable of upregulating glucocerebrosidase expression
|
|
TW202508607A
(zh)
*
|
2023-05-19 |
2025-03-01 |
大陸商北京炫景瑞醫藥科技有限公司 |
雙股寡核苷酸及其共軛物和用途
|
|
TW202516004A
(zh)
|
2023-06-16 |
2025-04-16 |
瑞士商赫孚孟拉羅股份公司 |
調節ｊａｋ１表現之雙股寡核苷酸
|
|
WO2025036916A1
(en)
|
2023-08-16 |
2025-02-20 |
Les Laboratoires Servier |
Oligonucleotides for modulating kcnt1 expression
|